title: Reduction of laser-induced choroidal neovascularization by intravitreal vasohibin-1 in monkey eyes.
abstract: OBJECTIVE
  To determine whether intravitreal vasohibin-1 will reduce the grade of the choroidal neovascularization in monkey eyes.
  
  
  METHODS
  Choroidal neovascularizations were induced in 12 monkey eyes by laser photocoagulation. Three monkeys were evaluated for the safety of the vasohibin-1 injections, 6 monkeys for the effects of a single injection, and 3 monkeys for repeated injections of vasohibin-1. Ophthalmoscopy, fluorescein angiography, focal electroretinograms, and optical coherence tomography were used for the evaluations. The level of vascular endothelial growth factor in the aqueous was determined by enzyme-linked immunosorbent assay. Immunohistochemistry was performed.
  
  
  RESULTS
  An intravitreal injection of 10 μg of vasohibin-1 induced mild intraocular inflammation. Eyes with an intravitreal injection of 0.1 μg and 1.0 μg of vasohibin-1 had significant less fluorescein leakage from the choroidal neovascularizations and larger amplitude focal electroretinograms than that of vehicle-injected eyes. Similar results were obtained by repeated injections of 0.1 μg of vasohibin-1. Immunohistochemistry showed that vasohibin-1 was expressed mainly in the endothelial cells within the choroidal neovascularizations. The vascular endothelial growth factor level was not significantly altered by intravitreal vasohibin-1.
  
  
  CONCLUSIONS
  The reduction of the laser-induced choroidal neovascularizations and preservation of macular function in monkey by intravitreal vasohibin-1 suggest that it should be considered for suppressing choroidal neovascularizations in humans.
authors.affiliation: Division of Clinical Cell Therapy, United Center for Advanced Medical Research and Development, Department of Ophthalmology and Visual Science, Graduate School of Medicine, Tohoku University, Miyagi, Japan.
authors.forename: Hideyuki
authors.initials: H
authors.lastname: Onami
authors.forename: Nobuhiro
authors.initials: N
authors.lastname: Nagai
authors.forename: Shigeki
authors.initials: S
authors.lastname: Machida
authors.forename: Norihiro
authors.initials: N
authors.lastname: Kumasaka
authors.forename: Ryosuke
authors.initials: R
authors.lastname: Wakusawa
authors.forename: Yumi
authors.initials: Y
authors.lastname: Ishikawa
authors.forename: Hikaru
authors.initials: H
authors.lastname: Sonoda
authors.forename: Yasufumi
authors.initials: Y
authors.lastname: Sato
authors.forename: Toshiaki
authors.initials: T
authors.lastname: Abe
mesh_terms: D020533:Angiogenesis Inhibitors / Q000008:administration & dosage* / Q000378:metabolism; D000818:Animals; D018797:Cell Cycle Proteins / Q000008:administration & dosage* / Q000378:metabolism; D020256:Choroidal Neovascularization / Q000188:drug therapy* / Q000378:metabolism / Q000473:pathology / Q000503:physiopathology; D004195:Disease Models, Animal; D004596:Electroretinography / Q000187:drug effects; D004797:Enzyme-Linked Immunosorbent Assay; D005451:Fluorescein Angiography; D007150:Immunohistochemistry; D058449:Intravitreal Injections; D008251:Macaca; D009887:Ophthalmoscopy; D041623:Tomography, Optical Coherence; D042461:Vascular Endothelial Growth Factor A / Q000378:metabolism
chemical_list: D020533:Angiogenesis Inhibitors; D018797:Cell Cycle Proteins; C493181:VASH1 protein, human; D042461:Vascular Endothelial Growth Factor A